title: COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
abstract: BACKGROUND
  This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer.
  
  
  METHODS
  COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time points.
  
  
  RESULTS
  Overall, 1916 patients received upfront anastrozole. Mean arthralgia scores were increased from baseline at each visit up to 9 months. Compliance with anastrozole therapy gradually decreased over time from baseline to 9 months (P<0.001). At 9 months, investigators estimated that >95% of patients were compliant versus patient reports of <70%. There was a significant association between arthralgia mean scores and noncompliance at 6 months (P<0.0001), 9 months (P<0.0001), and overall (P<0.0001). Over time, new events or impairment of existing arthralgias were reported in 14% (3 months), 11% (6 months), and 9% (9 months) of patients.
  
  
  CONCLUSIONS
  Arthralgia is important in the clinical management of women with early breast cancer and may contribute to noncompliance and clinical outcomes.
  
  
  BACKGROUND
  NCT00857012.
authors.affiliation: Department of Gynecology, Endocrinology and Oncology, Philipps University of Marburg, Marburg.
authors.forename: P
authors.initials: P
authors.lastname: Hadji
authors.forename: C
authors.initials: C
authors.lastname: Jackisch
authors.forename: W
authors.initials: W
authors.lastname: Bolten
authors.forename: M
authors.initials: M
authors.lastname: Blettner
authors.forename: H J
authors.initials: HJ
authors.lastname: Hindenburg
authors.forename: P
authors.initials: P
authors.lastname: Klein
authors.forename: K
authors.initials: K
authors.lastname: König
authors.forename: R
authors.initials: R
authors.lastname: Kreienberg
authors.forename: W
authors.initials: W
authors.lastname: Rief
authors.forename: D
authors.initials: D
authors.lastname: Wallwiener
authors.forename: S
authors.initials: S
authors.lastname: Zaun
authors.forename: N
authors.initials: N
authors.lastname: Harbeck
mesh_terms: D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced / Q000453:epidemiology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D057915:Drug Substitution; D005260:Female; D006801:Humans; D015994:Incidence; D055118:Medication Adherence; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole
keywords: anastrozole; aromatase inhibitors; arthralgia; breast neoplasms; patient compliance